Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 78 clinical trials
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a

cancer
lung metastases
metastasis
pemetrexed
EGFR
  • 36 views
  • 23 Mar, 2022
  • 10 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR

epidermal growth factor receptor
growth factor
epidermal growth factor
EGFR
osimertinib
  • 114 views
  • 16 May, 2022
  • 265 locations
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

This phase III study is designed to evaluate the anticancer activity of capmatinib in combination with osimertinib compared to platinum-pemetrexed based doublet chemotherapy as second line

epidermal growth factor receptor
growth factor
epidermal growth factor
cancer chemotherapy
EGFR
  • 0 views
  • 30 Apr, 2022
  • 12 locations
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure.

alopecia
squamous non-small cell lung cancer
epidermal growth factor receptor
growth factor
kinase inhibitor
  • 7 views
  • 08 Apr, 2022
  • 103 locations
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC

lung carcinoma
durvalumab
stereotactic body radiation therapy
  • 208 views
  • 05 May, 2022
  • 158 locations
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).

targeted therapy
epidermal growth factor receptor
growth factor
kinase inhibitor
tyrosine
  • 10 views
  • 12 May, 2022
  • 77 locations
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

This is a prospective, randomised, positive-controlled, study to assess the neurocognitive function of upfront Osimertinib compared to whole-brain irradiation (WBI) plus Osimertinib in EGFR

  • 0 views
  • 11 Apr, 2021
  • 1 location
Reqorsa (Quaratusugene Ozeplasmid) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1)

The purpose of this randomized study is to determine the safety and efficacy of Reqorsa (quaratusugene ozeplasmid, formerly known as GPX-001) added to osimertinib in NSCLC patients with

metastasis
advanced lung cancer
serum bilirubin level
cancer chemotherapy
platelet count
  • 0 views
  • 01 May, 2022
  • 4 locations
Osimertinib In EGFR Mutant Lung Cancer

is: Osimertinib (Tagrisso)

metastasis
EGFR
ct scan
neutrophil count
osimertinib
  • 3 views
  • 23 Apr, 2022
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN)

20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with

  • 52 views
  • 19 Feb, 2022
  • 10 locations